US government purchases more doses of Lilly’s bamlanivimab-etesevimab combo

The US government has agreed to purchase a minimum of 100,000 doses of Eli Lilly’s bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together.

Bamlanivimab and etesevimab together recently received emergency use authorisation for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization.

Additionally, the National Institutes of Health (NIH) recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression.

The purchase agreement is for $210 million and doses will be delivered through March 31, 2021.

The US government will have the option to purchase up to an additional 1,100,000 doses through November 25, 2021, under the same terms as the base agreement and subject to agreement from Lilly, product availability and the medical need in the U.S.

This purchase adds to the supply of neutralizing antibodies already available for use in the US.

The government has already committed to purchase a total of 1,450,000 doses of bamlanivimab alone, which includes more than 1 million doses that have been delivered and an agreement to deliver 450,000 additional doses by March 31, 2021.

The government has said it will provide neutralizing antibodies at no out-of-pocket cost to patients, although healthcare facilities may charge a fee for the product’s administration.

Lilly will begin shipping these additional doses immediately.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news